CANDA Syndrome

CANDA syndrome—short for Chronic Ataxic Neuropathy with anti-Disialosyl antibodies. It belongs to the same family as CANOMAD (Chronic Ataxic Neuropathy with Ophthalmoplegia, IgM paraprotein, Cold Agglutinins and Disialosyl antibodies). In practice, CANDA is used when patients have the same antibody profile and sensory-ataxic neuropathy but lack the full CANOMAD picture, especially constant eye-movement paralysis (ophthalmoplegia). www.elsevier.com+2Orpha+2

CANDA syndrome is a rare, long-lasting, immune-mediated nerve disease. The body’s immune system makes IgM antibodies that target “disialosyl” sugar patterns on nerve cell fats called gangliosides (especially GD1b and GQ1b). These antibodies disturb the way sensory nerve fibers work. Over time, people slowly develop unsteady walking (sensory ataxia), loss of balance in the dark, numbness and tingling, and reduced or absent reflexes. Some people also have eye-movement problems, trouble swallowing, or slurred speech—then doctors may prefer the label CANOMAD—but the same antibody family is involved. The condition is chronic, can relapse or progress, and often links to a small amount of abnormal IgM protein in the blood (a monoclonal gammopathy). PubMed+2ASH Publications+2

CANDLE syndrome is a genetic, autoinflammatory disease that usually starts in infancy or early childhood. Children and adults get repeated fevers, painful red-purple skin patches and nodules (often on the face and limbs), and gradual loss of the normal fat layer under the skin (lipodystrophy). Many also develop muscle inflammation, joint pain or stiffness, growth delay, and signs that the immune system is in “overdrive,” especially a strong type-I interferon signal in blood tests. CANDLE is part of the PRAAS family, most often linked to damaging changes (variants) in PSMB8 and other proteasome genes. Without treatment, ongoing inflammation can lead to disability; with modern anti-inflammatory strategies—especially JAK-inhibitors under specialist care—many patients experience fewer flares and better function. printo.it+3PubMed+3PubMed+3

Another names

Doctors and papers may use several terms that point to the same clinical idea:

• Chronic ataxic neuropathy with disialosyl antibodies (CANDA). This name highlights the chronic, unsteady gait (ataxia) and the specific autoantibodies against disialosyl gangliosides (for example GD1b, GQ1b, sometimes GT1a). PubMed+1

• Chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. A longer way of saying the same thing, often used in the neurology literature. OUP Academic

• CANOMAD spectrum. CANDA is frequently discussed on a spectrum with CANOMAD, which adds ophthalmoplegia, an IgM monoclonal gammopathy (paraprotein), and cold agglutinins; many patients share the same anti-disialosyl antibody profile. ASH Publications+1

Types

Clinicians don’t have official “stages,” but they often group patients by features that guide testing and treatment:

1. By antibody target:
   • GD1b-predominant, GQ1b, GT1a, or mixed disialosyl patterns. The specific antibody sometimes predicts clinical features (for example, GD1b is strongly linked with sensory ataxia). PubMed

2. By ocular involvement:
   • CANDA (no persistent ophthalmoplegia) vs CANOMAD (with ophthalmoplegia). Same antibody family; eye findings help label choice. www.elsevier.com

3. By paraprotein status:
   • With IgM paraprotein (MGUS/“monoclonal gammopathy”) vs without. This matters because the paraprotein can act as a cold agglutinin and may influence treatment choices. ASH Publications

4. By disease course:
   • Relapsing-remitting vs slowly progressive, describing symptom pattern over months to years. PubMed

Causes

Strictly speaking, a single fixed “cause” is not known. CANDA reflects autoimmunity against nerve gangliosides. Below are common drivers, associations, and mechanisms that research and case series link to this condition:

1. Autoantibody attack on disialosyl gangliosides. IgM antibodies (often against GD1b/GQ1b) bind to nerve components and disrupt sensory nerve signaling. PubMed

2. Monoclonal IgM paraprotein (MGUS). A small, abnormal B-cell clone can produce the anti-ganglioside IgM that fuels the neuropathy. ASH Publications

3. Cross-reactivity after immune stimulation. As with other anti-ganglioside conditions, immune responses can sometimes misrecognize nerve lipids; this “molecular mimicry” mechanism is inferred from related syndromes. ScienceDirect

4. Anti-GD1b immune specificity. Strongly associated with sensory ataxia, suggesting GD1b-rich fibers are targeted. PubMed

5. Anti-GQ1b/GT1a antibodies. These can co-occur and may broaden symptoms (for example, bulbar or ocular signs). PubMed

6. Cold agglutinins (in CANOMAD spectrum). The same IgM paraprotein may also act as a cold agglutinin, part of the extended phenotype. ASH Publications

7. Immune system dysregulation with age. Many patients present in mid- to late-adulthood, when B-cell clones/MGUS become more common. PubMed

8. Paraproteinemic neuropathy overlap. CANDA overlaps biologically with other neuropathies tied to IgM paraproteins. ASH Publications

9. Potential infection triggers. Acute and chronic ataxic neuropathies with disialosyl antibodies share mechanisms with post-infectious neuropathies, though definite triggers are not consistent. ResearchGate

10. Paranodal injury. Ultrastructural studies suggest paranodopathy at nerve fiber junctions in related anti-disialosyl conditions. ScienceDirect

11. Complement activation. IgM binding can activate complement, damaging myelin or nodal regions (inferred from anti-ganglioside neuropathies). MedLink

12. Sensory fiber selectivity. Disrupted proprioceptive/vibration fibers create marked ataxia even when strength is preserved. PubMed

13. Chronic immune stimulation. Persistent antibody production maintains symptoms over years. PubMed

14. Coexisting autoimmune tendencies. As with many autoimmune neuropathies, background autoimmunity may be more common than in the general population. (Inferred across the spectrum.) ASH Publications

15. Genetic host factors (hypothesized). Not proven, but host immune genetics likely shape who makes these antibodies. (Inference from autoimmunity.) ASH Publications

16. B-cell clonal expansion. Even small clones can secrete pathogenic anti-ganglioside IgM. ASH Publications

17. Axonal/myelin interface vulnerability. Disialosyl-rich regions at nodes/paranodes are target-dense areas. ScienceDirect

18. Overlap with CANOMAD features. The same immune process can extend to ocular/bulbar nerves in some patients. ASH Publications

19. Temperature-related hemolysis role (rare, spectrum). In CANOMAD, cold agglutinins can add systemic features; mechanism overlaps with the same IgM. ASH Publications

20. Time (chronicity). Ongoing exposure to the autoantibody, not a single event, is what maintains the neuropathy. PubMed

Symptoms

1. Unsteady walking (sensory ataxia). People feel “wobbly,” worse in the dark or with eyes closed, because position sense is impaired. Orpha

2. Frequent imbalance and falls. Loss of joint and tendon sense makes it easy to misstep. Orpha

3. Numbness and tingling (hands/feet, sometimes around the mouth). Sensory fibers are the main target. GARD Information Center

4. Reduced or absent reflexes. Tendon reflexes fade as sensory arcs fail. Orpha

5. “Heavy” or clumsy legs without true weakness. Coordination fails even when muscles are strong. PubMed

6. Eye-movement problems (in the spectrum). Some patients—more often labeled CANOMAD—develop ophthalmoplegia causing double vision. ASH Publications

7. Blurred vision/oscillopsia. Eye movement instability can make the world “bounce.” ASH Publications

8. Slurred speech (dysarthria). When bulbar pathways are involved within the same spectrum. GARD Information Center

9. Difficulty swallowing (dysphagia). Bulbar sensory/motor coordination can be affected in spectrum cases. GARD Information Center

10. Vibration and position sense loss. Classic on exam—patients cannot tell joint position. Orpha

11. Pins-and-needles pain. Neuropathic sensations may accompany numbness. MedLink

12. Gait that “stomps” or looks wide-based. People compensate for lost feedback by widening stance. PubMed

13. Fatigue from constant effort to balance. Each step requires more visual and cognitive input. PubMed

14. Rare breathing muscle weakness. Uncommon but described in spectrum disorders. GARD Information Center

15. Slow progression or relapses. Symptoms often wax and wane or creep forward over years. PubMed

Diagnostic tests

A. Physical examination (bedside assessment)

1. Gait and balance exam. The clinician watches how you walk and stand; a wide-based, unsteady gait suggests sensory ataxia. Orpha

2. Romberg test. Standing with feet together and eyes closed; increased sway or falling means your body relies on vision because joint position sense is impaired. Orpha

3. Reflex testing. Reduced or absent ankle/knee jerks fit with sensory neuropathy. Orpha

4. Vibration and joint-position testing. A tuning fork and passive toe moves check large-fiber sensory loss. Orpha

5. Cranial nerve/eye-movement exam. To look for ophthalmoplegia or subtle ocular motor limits linked to the CANOMAD end of the spectrum. ASH Publications

B. Manual/functional tests

6. Heel-to-shin and finger-to-nose. Coordination tasks separate sensory ataxia (feedback problem) from cerebellar ataxia. PubMed

7. Timed up-and-go / 10-meter walk. Simple measures to monitor change over time. PubMed

8. Dynamic gait index or Berg balance scale. Structured balance tools used in rehab follow-up. PAGEPress

C. Laboratory and pathological tests

9. Serum anti-ganglioside antibody panel. Looks for IgM anti-GD1b, anti-GQ1b, and related disialosyl antibodies—the key laboratory hallmark. PubMed

10. Serum protein electrophoresis and immunofixation (SPEP/IFE). Searches for an IgM monoclonal protein (paraprotein) that often accompanies this condition. ASH Publications

11. Cold agglutinin screen (when suspected). In the CANOMAD spectrum, the same IgM can act as a cold agglutinin. ASH Publications

12. Routine labs (B12, TSH, HbA1c, autoimmune markers). Rule out other causes of sensory ataxia so you don’t miss a treatable mimic. MedLink

13. CSF analysis (lumbar puncture). May show elevated protein with relatively few cells in immune-mediated neuropathies; mainly used to exclude other problems. MedLink

14. Bone marrow evaluation (selected cases). If a paraprotein is present or blood counts are abnormal, marrow studies may look for a clone driving IgM production. ASH Publications

D. Electrodiagnostic tests

15. Nerve conduction studies (NCS). Often reveal a sensory-predominant, demyelinating or mixed pattern; helps confirm a large-fiber sensory neuropathy. ASH Publications

16. Electromyography (EMG). Checks muscle electrical activity; supports the pattern and rules out other neuromuscular disease. MedLink

17. Somatosensory evoked potentials (SSEPs). Track sensory signals from limb to brain; they can demonstrate slowed or blocked pathways seen in sensory ataxia. (Applied in research/selected clinics.) MedLink

E. Imaging tests

18. MRI brain and spine. Mostly to exclude cerebellar or spinal cord causes of ataxia; in CANDA the imaging is usually normal or nonspecific. MedLink

19. Nerve ultrasound or MRI neurography (advanced centers). May show thickened or inflamed segments in immune neuropathies; supportive rather than diagnostic. MedLink

20. Autonomic testing (tilt table, sweat test) when symptoms suggest. Some patients report autonomic features; testing documents involvement and excludes mimics. MedLink

Non-pharmacological treatments (therapies & others)

These measures support (but do not replace) specialist drug therapy. Always personalize with your rheumatology/dermatology team.

1. Flare diary & trigger tracking — note fever days, infections, cold exposure, stressful events; patterns guide dose adjustments and clinic timing. PubMed

2. Vaccination planning — with the care team, keep inactivated vaccines up-to-date; time shots away from major immunosuppression and flares. Journal of Rheumatology

3. Infection-prevention hygiene — meticulous handwashing, prompt treatment of minor infections to avoid flare provocation. Journal of Rheumatology

4. Thermal protection — layered clothing and avoiding prolonged cold may lessen panniculitis triggers. termedia.pl

5. Skin care routines — gentle cleansers, emollients, sun protection to reduce irritation and post-inflammatory changes. termedia.pl

6. Physical therapy (PT) — stretching and low-impact strengthening to prevent contractures and maintain function; use goniometry to track. PubMed

7. Occupational therapy (OT) — joint protection strategies, splints for contracture prevention, energy-conservation planning for school/work. PubMed

8. Nutrition support — adequate calories and protein to counter weight loss and support growth; consider dietitian referral in pediatric cases. PubMed

9. Psychological support — coping skills, body-image counseling, school accommodations; chronic visible skin disease can be distressing. termedia.pl

10. Heat and gentle massage during post-flare stiffness (avoid when skin is acutely inflamed). termedia.pl

11. Sleep optimization — consistent routines help fatigue and pain sensitivity. termedia.pl

12. Anti-inflammatory eating pattern — balanced whole foods; avoid extreme diets; tailor to growth needs (no proven disease-specific diet). Journal of Rheumatology

13. School/work action plan — letters for excused absences and activity adjustments during flares. termedia.pl

14. Telehealth check-ins during dose changes to catch flares early (shown important with baricitinib tapering). PubMed

15. Sun/UV caution if on photosensitizing medicines; follow label guidance. FDA Access Data

16. Household illness protocols — masks/respiratory etiquette during family viral outbreaks while on immunosuppressants. Journal of Rheumatology

17. Falls-risk and deconditioning prevention — gradual activity plans after severe flares. PMC

18. Wound care basics for ulcerated lesions to prevent secondary infection. termedia.pl

19. Regular dental/eye checks if dry mouth/eye or steroid use; mitigate treatment side effects. Journal of Rheumatology

20. Family genetic counseling to understand inheritance and testing options. PubMed

---

Drug treatments

There is no FDA-approved medicine specifically for CANDLE/PRAAS. Treatments are off-label, guided by case series and mechanistic rationale. The strongest modern signal is with JAK inhibitors (e.g., baricitinib), which dampen the type-I interferon pathway; dose reductions can precipitate flares, so careful monitoring is essential. Always use under expert supervision and follow each drug’s FDA label for safety/monitoring. PMC+1

1. Baricitinib (OLUMIANT; JAK1/2 inhibitor). Purpose: blunt interferon-driven inflammation; often reduces fevers/skin lesions and improves labs. Mechanism: blocks JAK-STAT signaling downstream of type-I IFN and other cytokines. Key safety from label: boxed warnings for serious infections, malignancy, MACE, thrombosis; monitor CBC, LFTs, lipids; screen for TB and viral hepatitis. Typical adult RA dosing is 2–4 mg daily; PRAAS dosing is individualized in specialist centers. FDA Access Data+2FDA Access Data+2

2. Ruxolitinib (JAKAFI; JAK1/2 inhibitor). Purpose: alternative JAK inhibitor used off-label in interferonopathies. Mechanism: similar JAK-STAT blockade. Label highlights: cytopenias, infections, lipid changes; CYP3A4 interactions; dose adjustments for cytopenias/renal/hepatic issues. FDA Access Data+1

3. Tofacitinib (XELJANZ; JAK1/3 inhibitor). Purpose: JAK pathway suppression when others are unsuitable. Mechanism: inhibits signaling for multiple cytokines. Label highlights: infections, malignancy, thrombosis risk; avoid combining with biologic DMARDs; dose per indication/renal function. FDA Access Data+1

4. Upadacitinib (RINVOQ; selective JAK1 inhibitor). Purpose: interferon-pathway and cytokine blockade; emerging case experience. Label highlights: serious infection/MACE warnings similar to class; monitor labs; extended-release dosing. FDA Access Data+1

5. Anakinra (KINERET; IL-1 receptor antagonist). Purpose: some PRAAS patients tried IL-1 blockade; variable benefit. Mechanism: blocks IL-1α/β signaling. Label highlights: neutropenia risk, injection-site reactions; daily subcutaneous dosing; infection precautions. FDA Access Data+1

6. Canakinumab (ILARIS; IL-1β monoclonal). Purpose: longer-interval IL-1 blockade; mixed results in interferonopathies. Mechanism: neutralizes IL-1β. Label highlights: serious infections, immunizations guidance; subcutaneous every 4–8 weeks (per indication). FDA Access Data+1

7. Tocilizumab (ACTEMRA; IL-6 receptor blocker). Purpose: target IL-6–driven inflammation and acute-phase reactants; responses vary. Label highlights: neutropenia, liver enzyme elevations, lipid changes; IV or SC dosing schedules by indication. FDA Access Data+1

8. Sarilumab (KEVZARA; IL-6 receptor blocker). Purpose: alternative IL-6 blockade. Label highlights: infection warnings; neutropenia/hepatotoxicity monitoring; SC every 2 weeks. FDA Access Data+1

9. TNF inhibitors (adalimumab/HUMIRA; class includes etanercept, infliximab). Purpose: occasionally tried; many interferonopathies respond poorly to TNF blockade, but individual cases differ. Label highlights: serious infections (including TB), demyelination, HF risk; SC or IV per product. FDA Access Data

10. Short-course systemic corticosteroids (e.g., prednisone/modified-release RAYOS). Purpose: quickly suppress severe flares while steroid-sparing agents are optimized. Label highlights: hyperglycemia, hypertension, infection, growth effects; use the lowest effective dose for the shortest time. termedia.pl

 In a disease this rare, quality evidence concentrates around JAK inhibition with supportive biologics in select cases. I prioritized medicines with the strongest mechanistic fit and label-anchored safety. If you’d like, I can expand with additional agents (e.g., IVIG, sirolimus, methotrexate, mycophenolate) and provide FDA-label citations where applicable.

---

Dietary molecular supplements

No supplement treats CANDLE directly. The goal is general metabolic and bone health under medical supervision; avoid interactions with immunosuppressants.

1. Vitamin D (dose per level) — supports bone/immune health; monitor 25-OH D. Journal of Rheumatology

2. Calcium (diet first; supplements as needed) — protect bone if steroids are used. Journal of Rheumatology

3. Omega-3 fatty acids — modest anti-inflammatory effect; choose purified products to avoid contaminants. Journal of Rheumatology

4. Probiotics/fermented foods — gut comfort during immunosuppression; evidence general, not CANDLE-specific. Journal of Rheumatology

5. Folate/B-complex if on methotrexate or with poor intake. Journal of Rheumatology

6. Protein supplementation (dietitian-guided) for growth or myositis recovery. PubMed

7. Iron only if iron-deficiency is proven (not for anemia of inflammation). Journal of Rheumatology

8. Magnesium for muscle comfort if low. Journal of Rheumatology

9. Zinc if deficient; monitor copper with high-dose zinc. Journal of Rheumatology

10. Multivitamin (age-appropriate) when appetite is poor; avoid mega-doses. Journal of Rheumatology

---

Immune booster / regenerative / stem-cell drugs

There are no approved “immune-boosting” or stem-cell drugs for CANDLE. Stem-cell therapies are not standard of care and may be risky. What helps most is reducing the overactive interferon pathway with targeted anti-inflammatory medicines under expert supervision. If you see products marketed as “regenerative” for PRAAS, treat them with caution and discuss with a specialist. Journal of Rheumatology

---

Surgeries (when and why)

Surgery is not a treatment for CANDLE itself, but procedures may be considered for complications:

1. Contracture release or tendon-lengthening (severe fixed joint limitation despite PT/OT). Goal: improve function and pain. PubMed

2. Skin/soft-tissue procedures for non-healing ulcerations or scarring after panniculitis. Goal: wound closure, infection prevention. termedia.pl

3. Biopsy procedures (skin/muscle) to clarify diagnosis during active disease. Goal: rule out infection/vasculitis. termedia.pl

4. Feeding-tube placement (rare) if severe growth failure and poor intake. Goal: nutrition support. PubMed

5. Port/central line (selected cases) to facilitate recurrent infusions/labs—balance against infection risk. Journal of Rheumatology

---

Preventions (practical, everyday)

1. Early infection treatment and masking during outbreaks when on immunosuppressants. Journal of Rheumatology

2. Stay current with inactivated vaccines; coordinate timing around biologics/JAK inhibitors. Journal of Rheumatology

3. Avoid unnecessary cold exposure if it triggers skin flares. termedia.pl

4. Hands-off on raw/undercooked foods during high-dose immunosuppression. Journal of Rheumatology

5. Routine dental care to prevent oral infection triggers. Journal of Rheumatology

6. Monitor labs on schedule (CBC, LFTs, lipids) when taking JAK/biologics. FDA Access Data

7. Sun protection if photosensitive or on photosensitizing meds. FDA Access Data

8. Sick-day plans (who to call, what tests to get, when to hold meds). PubMed

9. Adherence tools (pill boxes, reminders) to avoid missed doses and rebound flares. PubMed

10. Family education—knowing early flare signs speeds care. termedia.pl

---

When to see a doctor (or seek urgent care)

• High fever, shaking chills, new cough, painful urination or any sign of infection while on JAK inhibitors or biologics—same day contact, because labels warn about serious infections. FDA Access Data

• Sudden shortness of breath, chest pain, severe headache, one-sided weakness, or leg swelling—possible clot/MACE signals listed in JAK-inhibitor warnings—urgent evaluation. FDA Access Data

• Rapidly spreading skin redness, deep ulcers, or severe pain—rule out bacterial infection. termedia.pl

• Persistent flare despite treatment changes or after a dose reduction of baricitinib—flares are documented; call your team. PubMed

• New vision changes, severe abdominal pain, or unusual bleeding/bruising on therapy—prompt review and labs. FDA Access Data

---

What to eat & what to avoid

1. Do eat: balanced meals with lean proteins, legumes, whole grains, fruits, and vegetables to support growth and muscle recovery. Avoid: extreme restrictive diets. Journal of Rheumatology

2. Do prefer omega-3-rich fish (well-cooked). Avoid raw/undercooked meats/eggs/sushi during high-risk periods. Journal of Rheumatology

3. Do keep calcium and vitamin D adequate (diet first). Avoid excess soda and very high salt if on steroids. Journal of Rheumatology

4. Do hydrate well, especially in fever days. Avoid high-caffeine energy drinks that disrupt sleep. Journal of Rheumatology

5. Do small, frequent meals if appetite is low. Avoid “immune boosters” making unproven claims. Journal of Rheumatology

6. Do check labels for grapefruit if using drugs with CYP3A4 issues (e.g., ruxolitinib). Avoid interactions. FDA Access Data

7. Do food-safety basics (handwashing, fridge temps). Avoid buffet-style leftovers if immunosuppressed. Journal of Rheumatology

8. Do iron-rich foods only if iron-deficient; otherwise anemia is inflammatory. Journal of Rheumatology

9. Do keep a diet diary around medication changes to spot triggers for GI upset. PubMed

10. Do see a dietitian for child growth or lipodystrophy-related nutrition needs. PubMed

---

Frequently asked questions

1. Is CANDLE contagious? No. It’s genetic, not an infection. PubMed

2. Is there a cure? Not yet. Treatment aims to control inflammation, reduce flares, and protect growth and function. PMC

3. Why JAK inhibitors? They turn down the interferon pathway, a core driver in PRAAS. PMC

4. Will stopping baricitinib suddenly cause problems? Dose reductions/interruptions have been linked to rebound flares in PRAAS; never change doses without your team. PubMed

5. Do TNF blockers work? Often less effective than JAK or IL-1/IL-6 strategies, but individual responses vary. Journal of Rheumatology

6. Can diet fix it? No diet cures CANDLE, but balanced nutrition helps recovery and bone/muscle health. Journal of Rheumatology

7. Is it autoimmune? It’s autoinflammatory—the innate immune system is overactive; autoantibodies are usually absent. Journal of Rheumatology

8. Will my child grow normally? Growth can lag if inflammation is uncontrolled; better control often improves growth patterns. PubMed

9. Do we need genetic testing? It confirms diagnosis, guides counseling, and helps access targeted therapy. PubMed

10. What about vaccines? Keep inactivated vaccines up-to-date; live vaccines depend on current therapy—ask your specialist. Journal of Rheumatology

11. How often are labs needed on JAK/biologics? Regular CBC/LFT/lipids at intervals set by the label and clinic protocol. FDA Access Data

12. Is school PE safe? Yes, as tolerated; adjust during flares and contracture rehab. PubMed

13. Could this be misdiagnosed as infection? Early on, yes; biopsy and genetics help clarify. termedia.pl

14. Are clinical trials available? Trials in related interferonopathies/JAK inhibitors appear intermittently (e.g., baricitinib/NNS). Check ClinicalTrials.gov. ClinicalTrials

15. Where can I learn more? Recent reviews in rheumatology/dermatology journals cover PRAAS/CANDLE updates. termedia.pl+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 10, 2025.